| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Departments of Respiratory Disease and Laboratory Medicine, First Municipal People's Hospital of Guangzhou, 1 Panfu Road, Guangzhou, People's Republic of China 2Eighth Municipal People's Hospital of Guangzhou, 627 Dongfeng Dong Road, Guangzhou, 510180, People's Republic of China 3Second Affiliated Hospital of Guangzhou Medical College, 250 Changgang Dong Road, Guangzhou, 510655, People's Republic of China 4Guangzhou Red-Cross Hospital, 396 Tongfu Zhong Road, Guangzhou, 510220, China 5Sixth Municipal People's Hospital of Guangzhou, 19 Yuanchu Xijie, Tianhe Guangzhou, 510260, People's Republic of China 6Division of Immunity and Infection, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
Correspondence Z. Zhao zhaozw1963{at}yahoo.com.cn
Received May 22, 2003
Accepted June 11, 2003
Severe acute respiratory syndrome (SARS), now known to be caused by a coronavirus, probably originated in Guangdong province in southern China in late 2002. The first major outbreak occurred in Guangzhou, the capital of Guangdong, between January and March 2003. This study reviews the clinical presentation, laboratory findings and response to four different treatment protocols. Case notes and laboratory findings were analysed and outcome measures were collected prospectively. The SARS outbreak in Guangdong province and the outbreak in Guangzhou associated with hospitals in the city are described, documenting clinical and laboratory features in a cohort of 190 patients randomly allocated to four treatment regimens. Patients were infected by close contact in either family or health-care settings, particularly following procedures likely to generate aerosols of respiratory secretions (e.g. administration of nebulized drugs and bronchoscopy). The earliest symptom was a high fever followed, in most patients, by dyspnoea, cough and myalgia, with 24 % of patients complaining of diarrhoea. The most frequent chest X-ray changes were patchy consolidation with progression to bilateral bronchopneumonia over 5–10 days. Thirty-six cases developed adult respiratory distress syndrome (ARDS), of whom 11 died. There was no response to antibiotics. The best response (no deaths) was seen in the group of 60 patients receiving early high-dose steroids and nasal CPAP (continuous airway positive pressure) ventilation; the other three treatment groups had significant mortality. Cross-infection to medical and nursing staff was completely prevented in one hospital by rigid adherence to barrier precautions during contact with infected patients. The use of rapid case identification and quarantine has controlled the outbreak in Guangzhou, in which more than 350 patients have been infected. Early administration of high-dose steroids and CPAP ventilation appears to offer the best supportive treatment with a reduced mortality compared with other treatment regimens.
This article has been cited by other articles:
|
|
 |
|
  J. McCracken Should noninvasive ventilation be considered a high-risk procedure during an epidemic? Can. Med. Assoc. J., November 10, 2009; 181(10): 663 - 664. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Khanolkar, S. M. Hartwig, B. A. Haag, D. K. Meyerholz, L. L. Epping, J. S. Haring, S. M. Varga, and J. T. Harty Protective and Pathologic Roles of the Immune Response to Mouse Hepatitis Virus Type 1: Implications for Severe Acute Respiratory Syndrome J. Virol., September 15, 2009; 83(18): 9258 - 9272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Khanolkar, S. M. Hartwig, B. A. Haag, D. K. Meyerholz, J. T. Harty, and S. M. Varga Toll-Like Receptor 4 Deficiency Increases Disease and Mortality after Mouse Hepatitis Virus Type 1 Infection of Susceptible C3H Mice J. Virol., September 1, 2009; 83(17): 8946 - 8956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Simonds and D. K. Sokol Lives on the line? Ethics and practicalities of duty of care in pandemics and disasters Eur. Respir. J., August 1, 2009; 34(2): 303 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Nichols, A. J. Peck Campbell, and M. Boeckh Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances Clin. Microbiol. Rev., April 1, 2008; 21(2): 274 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. C. Cheng, S. K. P. Lau, P. C. Y. Woo, and K. Y. Yuen Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection Clin. Microbiol. Rev., October 1, 2007; 20(4): 660 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Carter A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza J. Med. Microbiol., July 1, 2007; 56(7): 875 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhou, D. Xu, X. Li, H. Li, M. Shan, J. Tang, M. Wang, F.-S. Wang, X. Zhu, H. Tao, et al. Screening and Identification of Severe Acute Respiratory Syndrome-Associated Coronavirus-Specific CTL Epitopes J. Immunol., August 15, 2006; 177(4): 2138 - 2145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Grace, K. Hershenfield, E. Robertson, and D. E. Stewart The Occupational and Psychosocial Impact of SARS on Academic Physicians in Three Affected Hospitals Psychosomatics, October 1, 2005; 46(5): 385 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Ghani, C. A. Donnelly, D. R. Cox, J. T. Griffin, C. Fraser, T. H. Lam, L. M. Ho, W. S. Chan, R. M. Anderson, A. J. Hedley, et al. Methods for Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease Am. J. Epidemiol., September 1, 2005; 162(5): 479 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Levy, M. S. Baylor, G. R. Bernard, R. Fowler, T. J. Franks, F. G. Hayden, R. Helfand, S. E. Lapinsky, T. R. Martin, M. S. Niederman, et al. Clinical Issues and Research in Respiratory Failure from Severe Acute Respiratory Syndrome Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 518 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Maki SARS Revisited: The Challenge of Controlling Emerging Infectious Diseases at the Local, Regional, Federal, and Global Levels Mayo Clin. Proc., November 1, 2004; 79(11): 1359 - 1366. [PDF]
|
|
|
|
 |
|
 X. Tan, S. Li, C. Wang, X. Chen, and X. Wu Severe Acute Respiratory Syndrome epidemic and change of people's health behavior in China Health Educ. Res., October 1, 2004; 19(5): 576 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W C Yu, D S C Hui, and M Chan-Yeung Antiviral agents and corticosteroids in the treatment of severe acute respiratory syndrome (SARS) Thorax, August 1, 2004; 59(8): 643 - 645. [Full Text] [PDF]
|
|
|
|
 |
|
 C C Mok and K Y Ying Lupus pneumonitis or severe acute respiratory syndrome? Lupus, July 1, 2004; 13(7): 549 - 553. [Abstract] [PDF]
|
|
|
|
 |
|
 J. S.M. Peiris, K. Y. Yuen, A. D.M.E. Osterhaus, and K. Stohr The Severe Acute Respiratory Syndrome N. Engl. J. Med., December 18, 2003; 349(25): 2431 - 2441. [Full Text] [PDF]
|
|
|
|
|
|
G. Zhaori Antiviral treatment of SARS: Can we draw any conclusions? Can. Med. Assoc. J., November 25, 2003; 169(11): 1165 - 1166. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Hawkey, S. Bhagani, and S. H. Gillespie Severe acute respiratory syndrome (SARS): breath-taking progress J. Med. Microbiol., August 1, 2003; 52(8): 609 - 613. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | J MED MICROBIOL | MICROBIOLOGY | J GEN VIROL | ALL SGM JOURNALS |
